PGxAI Admitted to Creative Destruction Lab (CDL) Seattle - Computational Health 2025-2026

PALO ALTO, Calif., Sep. 22, 2025 - PGxAI has been admitted to the Creative Destruction Lab (CDL) Seattle program for the 2025-2026 cycle, joining the Computational Health stream hosted at the Foster School of Business, University of Washington. The objectives-based CDL program pairs founders with experienced operators, scientists, and investors to set measurable milestones and accelerate commercialization.

About PGxAI
PGxAI is an AI-driven precision-medicine company that transforms multi-omics and clinical data into real-time, gene-guided prescribing support for health systems, payors, and life sciences partners.